This page contains Forward Looking Statements made as of June 6, 2016.*
Below is a list of our current clinical studies listed by stage and indication.
Phase 3 - Sickle Cell Disease
In February 2016, we completed patient enrollment in our Phase 3 clinical study of vepoloxamer for the treatment of vaso-occlusive crisis in patients with in sickle cell disease, known as the EPIC study. Top-line data from EPIC is forthcoming. For more information, please visit theEPICstudy.com or the study detail page at ClinicalTrials.gov.**
Phase 2 - Chronic Heart Failure
Our ongoing, randomized, double-blind, placebo-controlled, multicenter Phase 2 study of vepoloxamer will enroll approximately 150 ambulatory patients with chronic heart failure (LV ejection fraction ≤ 35%). Patients in this study are randomized into one of three approximately 50-patient study arms and receive one of two dose levels of a new formulation of vepoloxamer or placebo control intravenously over three hours in an outpatient setting or short-stay inpatient unit, depending on local practice and resource availability. For more information, please visit the study detail page at ClinicalTrials.gov.**
The Importance of Clinical Trials
(double-click video for full-screen view)
*Forward-Looking Statements: Any statement contained in this page that is not a statement of historical fact should be considered a forward-looking statement that speaks only as the date of the post in which it is made. Forward-looking statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products. Please see the Terms and Conditions of Use page of this website for more information about forward-looking statements.
**Links to third-party Internet sites are provided on this site for your convenience. Such sites are not under our control. Linking to third-party Internet sites does not indicate or imply any endorsement of or sponsorship by us of such sites or the information, products or services offered on or through such sites. We expressly disclaim any responsibility for the privacy policies and information collection practices of such third-party sites, as well as the content, accuracy of information and/or quality of such sites, including any products and/or services provided by or advertised on such sites. You are responsible for complying with all terms and conditions governing the use of such third-party Internet sites.